DE3413608A1
(en)
*
|
1984-04-11 |
1985-10-24 |
Hoechst Ag, 6230 Frankfurt |
IMPLANTABLE PREPARATIONS OF REGULATORY PEPTIDES WITH CONTROLLED RELEASE AND METHOD FOR THE PRODUCTION THEREOF
|
US5137874A
(en)
*
|
1985-07-29 |
1992-08-11 |
American Cyanamid Co. |
Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
|
IL79134A
(en)
*
|
1985-07-29 |
1991-06-10 |
American Cyanamid Co |
Continuous release peptide implants for parenteral administration
|
US4761289A
(en)
*
|
1986-10-10 |
1988-08-02 |
International Minerals & Chemical Corp. |
Sustained release implant and method for preparing same
|
ATE151638T1
(en)
|
1987-02-20 |
1997-05-15 |
Genentech Inc |
METHODS AND PREPARATIONS FOR USE OF HIV ENV POLYPEPTIDES AND ANTIBODIES
|
DE3712095A1
(en)
*
|
1987-04-10 |
1988-10-20 |
Lentia Gmbh |
BINDER-FREE GRANULES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES
|
DE3811231A1
(en)
*
|
1988-04-02 |
1989-10-12 |
Beiersdorf Ag |
Surgical implants
|
EP0423484B1
(en)
*
|
1989-10-16 |
1993-11-03 |
PCD-Polymere Gesellschaft m.b.H. |
Tablet with sustained release
|
US5470582A
(en)
*
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
JP2651320B2
(en)
*
|
1992-07-16 |
1997-09-10 |
田辺製薬株式会社 |
Method for producing sustained-release microsphere preparation
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
DE4423131A1
(en)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US5674888A
(en)
*
|
1995-06-07 |
1997-10-07 |
University Of California |
Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
|
US5599535A
(en)
*
|
1995-06-07 |
1997-02-04 |
Regents Of The University Of California |
Methods for the cyto-protection of the trabecular meshwork
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US5985830A
(en)
*
|
1996-09-16 |
1999-11-16 |
Dalhousie University |
Use of IGF-I for the treatment of kidney disorders
|
DK0939804T4
(en)
|
1996-10-25 |
2011-07-18 |
Human Genome Sciences Inc |
Neutrokine-alpha
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
JP2002512521A
(en)
|
1997-05-30 |
2002-04-23 |
ヒューマン ジノーム サイエンシーズ,インコーポレイテッド |
32 human secreted proteins
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
EP1015488B1
(en)
|
1997-09-17 |
2009-09-09 |
Human Genome Sciences, Inc. |
Interleukin-17 receptor-like protein
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
EP1064382B1
(en)
|
1998-03-17 |
2008-08-20 |
Genentech, Inc. |
Polypeptides homologous to vegf and bmp1
|
WO1999047538A1
(en)
|
1998-03-19 |
1999-09-23 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
AU3501700A
(en)
|
1999-02-26 |
2000-09-14 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
WO2000058479A1
(en)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Beta secretase genes and polypeptides
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
CA2377585A1
(en)
|
1999-06-28 |
2001-01-04 |
Genentech, Inc. |
Methods for making apo-2 ligand using divalent metal ions
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
EP1832599A3
(en)
|
2000-04-12 |
2007-11-21 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
JP2004519205A
(en)
|
2000-06-28 |
2004-07-02 |
アムジェン インコーポレイテッド |
Thymic stromal lymphopoietin receptor molecule and its use
|
EP2351840A1
(en)
|
2000-11-28 |
2011-08-03 |
Amgen Inc. |
Polypeptides involved in immune response
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
DE122010000047I1
(en)
|
2001-06-26 |
2011-05-05 |
Amgen Fremont Inc |
ANTIBODIES AGAINST OPGL
|
US7767786B2
(en)
|
2001-08-24 |
2010-08-03 |
Neuren Pharmaceuticals Ltd. |
Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
|
ATE557092T1
(en)
|
2001-08-29 |
2012-05-15 |
Genentech Inc |
BV8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
|
US7459432B2
(en)
|
2001-09-24 |
2008-12-02 |
Imperial College Innovations Ltd. |
Modification of feeding behavior
|
JP2005508162A
(en)
|
2001-10-02 |
2005-03-31 |
ジェネンテック・インコーポレーテッド |
Apo-2 ligand variants and methods of use
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
ATE423571T1
(en)
|
2001-10-12 |
2009-03-15 |
Schering Corp |
USE OF BISPECIFIC ANTIBODIES AGAINST AN ACTIVATIVE RECEPTOR FCEPSILONRI AND AGAINST AN INHIBITING RECEPTOR OX2RA (CD200RA) TO REGULATE IMMUNE RESPONSES
|
PT1450847E
(en)
|
2001-11-13 |
2011-01-05 |
Genentech Inc |
Apo2 ligand/ trail formulations and uses thereof
|
DK1463751T3
(en)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Albumin Fusion Proteins.
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
EP1474163A2
(en)
|
2002-01-10 |
2004-11-10 |
Imperial College Innovations Limited |
Modification of feeding behavior
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
AU2003243139B2
(en)
|
2002-04-05 |
2007-06-21 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
EP1500665B1
(en)
|
2002-04-15 |
2011-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
METHODS FOR CONSTRUCTING scDb LIBRARIES
|
WO2003091424A1
(en)
|
2002-04-26 |
2003-11-06 |
Chugai Seiyaku Kabushiki Kaisha |
Method of screening agonistic antibody
|
WO2003099320A1
(en)
|
2002-05-24 |
2003-12-04 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US20060141561A1
(en)
|
2002-06-24 |
2006-06-29 |
Kelley Robert F |
Apo-2 ligand/trail variants and uses thereof
|
TWI347951B
(en)
|
2002-09-06 |
2011-09-01 |
Amgen Inc |
Therapeutic human anti-il-1r1 monoclonal antibody
|
US9809654B2
(en)
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
WO2004034988A2
(en)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
WO2004050683A2
(en)
|
2002-12-02 |
2004-06-17 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
MXPA05007019A
(en)
|
2002-12-30 |
2005-08-18 |
Amgen Inc |
Combination therapy with co-stimulatory factors.
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
AU2004207536B2
(en)
|
2003-01-24 |
2010-05-20 |
Elan Pharmaceuticals Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
JP4912144B2
(en)
|
2003-03-12 |
2012-04-11 |
ジェネンテック, インコーポレイテッド |
Use of BV8 and / or EG-VEGF to promote hematopoiesis
|
US8067544B2
(en)
|
2003-03-19 |
2011-11-29 |
Curagen Corporation |
Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
|
US7375076B2
(en)
|
2003-05-20 |
2008-05-20 |
The Regents Of The University Of Michigan |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
|
CA2530172A1
(en)
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
DK1648998T3
(en)
|
2003-07-18 |
2015-01-05 |
Amgen Inc |
Specific binding agents for hepatocyte growth factor
|
ES2373783T3
(en)
|
2003-09-12 |
2012-02-08 |
Tercica, Inc. |
METHODS FOR THE TREATMENT OF DEFICIENCY OF INSULIN SIMILAR GROWTH FACTOR 1 (IGF-1).
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP2311945A1
(en)
|
2003-10-14 |
2011-04-20 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibodies substituting for functional proteins
|
WO2005044188A2
(en)
|
2003-10-27 |
2005-05-19 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
AU2005211362B2
(en)
|
2004-02-02 |
2008-03-13 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
WO2005076843A2
(en)
|
2004-02-06 |
2005-08-25 |
Elan Pharmaceuticals, Inc. |
Methods and compositions for treating tumors and metastatic disease
|
US20050260679A1
(en)
|
2004-03-19 |
2005-11-24 |
Sirid-Aimee Kellerman |
Reducing the risk of human anti-human antibodies through V gene manipulation
|
EP1726647B1
(en)
|
2004-03-19 |
2015-01-07 |
GenomIdea, Inc. |
Gene promoting vascular endothelial cell growth
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
KR101347830B1
(en)
|
2004-05-23 |
2014-01-07 |
에이치엠아이, 인코포레이티드 |
Theramutein modulators
|
WO2005115438A1
(en)
|
2004-05-25 |
2005-12-08 |
Stryker Corporation |
Use of morphogenic proteins for treating cartilage defects
|
NZ582684A
(en)
|
2004-06-18 |
2011-05-27 |
Ambrx Inc |
Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
|
EP2298896A1
(en)
|
2004-06-22 |
2011-03-23 |
The Board of Trustees of the University of Illinois |
Methods of inhibiting tumor cell proliferation with FOXM1 siRNA
|
AU2005258335B2
(en)
|
2004-06-24 |
2011-03-17 |
Biogen Ma Inc. |
Treatment of conditions involving demyelination
|
ME00226B
(en)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
|
EP2329714A1
(en)
|
2004-08-03 |
2011-06-08 |
Biogen Idec MA Inc. |
Influence of TAJ in the neuronal functions
|
ES2414460T3
(en)
|
2004-08-04 |
2013-07-19 |
Amgen Inc. |
Antibodies for Dkk-1
|
JP5070052B2
(en)
|
2004-08-17 |
2012-11-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
PDE5 inhibitor composition and method for treating heart disease
|
NZ554142A
(en)
|
2004-10-06 |
2009-12-24 |
Agri Biotech Pty Ltd |
Antibody production method comprising inserting antigen releasing device into mammal so antibodies are released into its milk
|
JP4852773B2
(en)
|
2004-10-15 |
2012-01-11 |
国立大学法人三重大学 |
Liver regeneration / restoration control agent
|
DE602005025525D1
(en)
|
2004-11-17 |
2011-02-03 |
Amgen Inc |
COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13
|
EP1827446A4
(en)
|
2004-12-06 |
2011-01-12 |
Siga Technologies Inc |
Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
|
AU2005319404B2
(en)
|
2004-12-20 |
2011-10-20 |
Amgen Fremont Inc. |
Binding proteins specific for human Matriptase
|
RU2394839C2
(en)
|
2004-12-21 |
2010-07-20 |
Астразенека Аб |
Antibodies against angiopoietin-2 and use thereof
|
JP5425398B2
(en)
|
2004-12-22 |
2014-02-26 |
アンブレツクス・インコーポレイテツド |
Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides
|
JP2008525473A
(en)
|
2004-12-22 |
2008-07-17 |
アンブレツクス・インコーポレイテツド |
Modified human growth hormone
|
ES2395953T3
(en)
|
2005-01-26 |
2013-02-18 |
Amgen Fremont Inc. |
Antibodies to interleukin-1 beta
|
EP2824183B1
(en)
|
2005-04-08 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing bispecific antibodies
|
US20080009546A1
(en)
|
2005-05-06 |
2008-01-10 |
Chevron U.S.A. Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
|
WO2006124699A2
(en)
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
US20090028854A1
(en)
|
2005-06-10 |
2009-01-29 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 SITE-DIRECTED MUTANT
|
JP5068167B2
(en)
|
2005-06-10 |
2012-11-07 |
中外製薬株式会社 |
Stabilizer for protein preparation containing meglumine and use thereof
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
PL2314623T3
(en)
|
2005-06-21 |
2012-11-30 |
Xoma Us Llc |
IL-1beta binding antibodies and fragments thereof
|
MX2008000253A
(en)
|
2005-07-08 |
2008-04-02 |
Biogen Idec Inc |
Sp35 antibodies and uses thereof.
|
KR20130023356A
(en)
|
2005-07-18 |
2013-03-07 |
메다렉스, 인코포레이티드 |
Human anti-b7rp1 neutralizing antibodies
|
CA2616537A1
(en)
|
2005-07-27 |
2007-02-01 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
WO2007142667A2
(en)
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
AR061400A1
(en)
|
2005-10-14 |
2008-08-27 |
Chugai Kabushiki Kaisha |
AGENTS TO DELETE THE DANE TO TRANSPLANTED ISLOTS AFTER THE ISLOT TRANSPLANT
|
WO2007046489A1
(en)
|
2005-10-21 |
2007-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for heart disease
|
AU2006311828B2
(en)
|
2005-11-04 |
2013-07-11 |
Biogen Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
CA2629453C
(en)
|
2005-11-10 |
2018-03-06 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
WO2007055378A1
(en)
|
2005-11-14 |
2007-05-18 |
Cell Signals Inc. |
Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
AR057582A1
(en)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
|
PT2339014E
(en)
|
2005-11-16 |
2015-10-13 |
Ambrx Inc |
Methods and compositions comprising non-natural amino acids
|
AR057941A1
(en)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
THERAPEUTIC AGENTS FOR PROSTATE CANCER
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
WO2007064882A2
(en)
|
2005-12-02 |
2007-06-07 |
Biogen Idec Ma Inc. |
Treatment of conditions involving demyelination
|
WO2008024128A2
(en)
|
2005-12-05 |
2008-02-28 |
Simon Delagrave |
Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents
|
ATE552853T1
(en)
|
2005-12-13 |
2012-04-15 |
Medimmune Ltd |
PROTEINS THAT SPECIFICALLY BIND INSULIN-LIKE GROWTH FACTORS AND THEIR APPLICATIONS
|
CN101370519B
(en)
|
2005-12-15 |
2013-07-24 |
阿斯利康(瑞典)有限公司 |
Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
|
CA2634974A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology, Ltd. |
Extended release of neuregulin for improved cardiac function
|
JPWO2007083644A1
(en)
|
2006-01-17 |
2009-06-11 |
ディナベック株式会社 |
Novel protein expression system
|
US8669345B2
(en)
|
2006-01-27 |
2014-03-11 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
AU2007208678B2
(en)
|
2006-01-27 |
2013-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for diseases involving choroidal neovascularization
|
WO2007116962A1
(en)
|
2006-04-07 |
2007-10-18 |
Osaka University |
Muscle regeneration promoter
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
EP2035030A2
(en)
|
2006-05-17 |
2009-03-18 |
Stryker Corporation |
Use of a soluble morphogenic protein complex for treating cartilage defects
|
ES2497641T3
(en)
|
2006-05-17 |
2014-09-23 |
The Ludwig Institute For Cancer Research |
Direction to the regulation of VEGF-B of fatty acid transporters to modulate human diseases
|
EP2049570B1
(en)
|
2006-06-01 |
2016-08-10 |
President and Fellows of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
RU2511406C2
(en)
|
2006-06-08 |
2014-04-10 |
Чугаи Сейяку Кабусики Кайся |
Preventive and therapeutic agent for inflammatory disease
|
AR061986A1
(en)
|
2006-07-13 |
2008-08-10 |
Chugai Pharmaceutical Co Ltd |
CELLULAR DEATH INDUCTIVE AGENTS
|
JP5175729B2
(en)
|
2006-07-21 |
2013-04-03 |
中外製薬株式会社 |
Kidney disease treatment
|
EP2412383A1
(en)
|
2006-07-28 |
2012-02-01 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
CL2007002225A1
(en)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
|
US9505823B2
(en)
|
2006-08-07 |
2016-11-29 |
TEV A Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
MX2009002523A
(en)
|
2006-09-08 |
2009-03-20 |
Ambrx Inc |
Modified human plasma polypeptide or fc scaffolds and their uses.
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
EP2503341A3
(en)
|
2006-11-14 |
2012-10-03 |
Genentech, Inc. |
Modulators of Neuronal Regeneration
|
CA2672049C
(en)
|
2006-12-08 |
2016-05-10 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against angptl3
|
TWI428346B
(en)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
US7695718B2
(en)
|
2006-12-20 |
2010-04-13 |
Xoma Technology Ltd. |
Methods for the treatment of IL-1β related diseases
|
EP2740744B1
(en)
|
2007-01-09 |
2018-03-28 |
Biogen MA Inc. |
Sp35 antibodies and uses thereof
|
RU2450829C2
(en)
|
2007-01-23 |
2012-05-20 |
Синсу Юниверсити |
Chronic rejection inhibitor
|
US9107884B2
(en)
|
2007-02-02 |
2015-08-18 |
Biogen Ma Inc. |
Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiation
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
US7947646B2
(en)
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
CL2008000719A1
(en)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO
|
WO2008121563A2
(en)
|
2007-03-30 |
2008-10-09 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
WO2008140026A1
(en)
|
2007-05-11 |
2008-11-20 |
Bizen Chemical Co., Ltd. |
Novel leukotriene receptor antagonist
|
EP1994927A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of viral disorders
|
EP1995227A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Spiro and other derivatives of diamondoids posessing therapeutic activity in the treatment of viral disorders
|
CN101932602B
(en)
|
2007-06-27 |
2017-05-24 |
新加坡国立大学 |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
JP5424330B2
(en)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
A therapeutic agent for ocular inflammatory diseases comprising an interleukin 6 receptor inhibitor as an active ingredient
|
SG10201500328QA
(en)
|
2007-08-21 |
2015-03-30 |
Amgen Inc |
Human c-fms antigen binding proteins
|
EP4248976A3
(en)
|
2007-08-23 |
2024-04-10 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
JOP20080381B1
(en)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
EP2497783A3
(en)
|
2007-09-26 |
2013-04-17 |
U3 Pharma GmbH |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
RU2490025C2
(en)
|
2007-10-02 |
2013-08-20 |
Чугаи Сейяку Кабусики Кайся |
Therapeutic agent used for graft-versus-host disease, containing interleukin-6 receptor inhibitor as active ingredient
|
PL2207568T3
(en)
|
2007-11-16 |
2018-01-31 |
Univ Rockefeller |
Antibodies specific for the protofibril form of beta-amyloid protein
|
US8946148B2
(en)
|
2007-11-20 |
2015-02-03 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
US8431127B2
(en)
|
2007-12-05 |
2013-04-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for treating pruritus comprising administering an NR10 antagonist
|
ES2834741T3
(en)
|
2007-12-05 |
2021-06-18 |
Chugai Pharmaceutical Co Ltd |
Anti-NR10 antibody and its use
|
EP2241333A1
(en)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
MX2010006823A
(en)
|
2007-12-20 |
2010-09-30 |
Xoma Technology Ltd |
Methods for the treatment of gout.
|
NZ586947A
(en)
|
2008-02-08 |
2012-11-30 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
|
JOP20190083A1
(en)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
Fgf21 mutant fusion polypeptides and uses thereof
|
JP5544290B2
(en)
|
2008-06-05 |
2014-07-09 |
独立行政法人国立がん研究センター |
Nerve infiltration inhibitor
|
US20110293520A1
(en)
|
2008-06-09 |
2011-12-01 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
|
EP2671891A3
(en)
|
2008-06-27 |
2014-03-05 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
DK2982695T3
(en)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
COMPOSITIONS CONCERNING ANTIBODIES AGAINST LINGO OR FRAGMENTS THEREOF
|
US10138283B2
(en)
|
2008-07-23 |
2018-11-27 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
EP2334702A2
(en)
|
2008-09-10 |
2011-06-22 |
Genentech, Inc. |
Methods for inhibiting ocular angiogenesis
|
RU2581962C2
(en)
|
2008-09-19 |
2016-04-20 |
Медиммун Ллк |
Targeted binding agents against dll4 and application thereof
|
CN102224238B
(en)
|
2008-09-26 |
2015-06-10 |
Ambrx公司 |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
CN102232085A
(en)
|
2008-09-26 |
2011-11-02 |
Ambrx公司 |
Modified animal erythropoietin polypeptides and their uses
|
CA2739663A1
(en)
|
2008-10-10 |
2010-05-15 |
Anaphore, Inc. |
Polypeptides that bind trail-r1 and trail-r2
|
PE20120021A1
(en)
|
2008-10-10 |
2012-02-10 |
Amgen Inc |
MUTANTS FGF21
|
WO2010048446A2
(en)
|
2008-10-22 |
2010-04-29 |
Genentech, Inc. |
Modulation of axon degeneration
|
EA201100832A1
(en)
|
2008-11-26 |
2011-12-30 |
Амген Инк. |
OPTIONS OF POLYPEPTIDES OF ACTIVIN IIB RECEPTOR AND THEIR APPLICATION
|
WO2010070136A2
(en)
|
2008-12-19 |
2010-06-24 |
Centre de Recherche Public de la Santé |
Novel caviidae allergens and uses thereof
|
US20110312872A1
(en)
|
2008-12-22 |
2011-12-22 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
WO2010072740A2
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
|
JO3382B1
(en)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
Human cgrp receptor binding antibodies
|
EP2385980B1
(en)
|
2009-01-08 |
2018-04-18 |
Albert Einstein College of Medicine, Inc. |
Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
|
US20110294733A1
(en)
|
2009-01-20 |
2011-12-01 |
Hanall Biopharma Co., Ltd. |
Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
JP2012517801A
(en)
|
2009-02-13 |
2012-08-09 |
ノバルティス アーゲー |
Biosynthetic cluster nucleic acid molecules encoding non-ribosomal peptide synthases and uses thereof
|
AU2010218152B2
(en)
|
2009-02-27 |
2015-04-09 |
Siga Technologies, Inc. |
Thienopyridine derivatives for the treatment and prevention of Dengue virus infections
|
JP2010210772A
(en)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
Method of manufacturing liquid crystal display device
|
US9724337B2
(en)
|
2009-04-21 |
2017-08-08 |
University Of Kentucky Research Foundation |
AG-205 for the treatment of breast cancer
|
NZ596037A
(en)
|
2009-05-05 |
2013-10-25 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
CA2760674A1
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
IN2012DN00352A
(en)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
EP2443145A1
(en)
|
2009-06-17 |
2012-04-25 |
Amgen, Inc |
Chimeric fgf19 polypeptides and uses thereof
|
WO2011013786A1
(en)
|
2009-07-31 |
2011-02-03 |
Maeda Shin |
Cancer metastasis inhibitor
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
CN102711772A
(en)
|
2009-10-16 |
2012-10-03 |
奥克兰联合服务有限公司 |
Anti-neoplastic uses of artemin antagonists
|
JP5746191B2
(en)
|
2009-10-19 |
2015-07-08 |
ハナル バイオファーマ カンパニーリミテッドHanAll Biopharma Co., Ltd. |
Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof and method for producing the same
|
CN104043126A
(en)
|
2009-10-22 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
Modulation of axon degeneration
|
MX341084B
(en)
|
2009-11-02 |
2016-08-05 |
Univ Washington |
Therapeutic nuclease compositions and methods.
|
EP2498804A4
(en)
|
2009-11-13 |
2013-05-08 |
Puget Sound Blood Ct |
Factor viii b cell epitope variants having reduced immunogenicity
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
CA2782814A1
(en)
|
2009-12-02 |
2011-06-09 |
Amgen Inc. |
Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho
|
UA109888C2
(en)
|
2009-12-07 |
2015-10-26 |
|
ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
CN107056929A
(en)
|
2009-12-21 |
2017-08-18 |
Ambrx 公司 |
Porcine somatotropin polypeptide and its purposes by modification
|
US20130053438A1
(en)
|
2010-01-19 |
2013-02-28 |
Universitat Innsbruck |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
US9090707B2
(en)
|
2010-01-27 |
2015-07-28 |
Children's Medical Center Corporation |
Pro-angiogenic fragments of prominin-1 and uses thereof
|
EP2533859B1
(en)
|
2010-02-10 |
2016-04-06 |
Nayacure Therapeutics Ltd |
Pharmaceutical compositions for the treatment and prevention of cancer
|
EP2865668A3
(en)
|
2010-02-19 |
2015-09-23 |
Siga Technologies, Inc. |
Inhibitors and methods of inhibiting bacterial and viral pathogens
|
WO2011119906A1
(en)
|
2010-03-26 |
2011-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HUMAN POLYOMAVIRUS 6 (HPyV6) AND HUMAN POLYOMAVIRUS 7 (HPyV7)
|
EP2554552B1
(en)
|
2010-03-26 |
2015-05-13 |
The University of Tokushima |
Novel anti-cd98 antibody and use thereof
|
US9517264B2
(en)
|
2010-04-15 |
2016-12-13 |
Amgen Inc. |
Human FGF receptor and β-Klotho binding proteins
|
US20130116304A1
(en)
|
2010-04-19 |
2013-05-09 |
Ernst R. Werner |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
WO2011139594A2
(en)
|
2010-04-27 |
2011-11-10 |
Medtronic, Inc. |
Artificial bursa for intra-articular drug delivery
|
WO2011139595A2
(en)
|
2010-04-27 |
2011-11-10 |
Medtronic, Inc. |
Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
|
EP3181692A1
(en)
|
2010-05-07 |
2017-06-21 |
Centre National De La Recherche Scientifique |
Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
|
US9273316B2
(en)
|
2010-05-21 |
2016-03-01 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
US20130149302A1
(en)
|
2010-05-28 |
2013-06-13 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for pancreatic cancer
|
RS63800B1
(en)
|
2010-05-28 |
2022-12-30 |
Chugai Pharmaceutical Co Ltd |
Antitumor t cell response enhancer
|
WO2011157819A2
(en)
|
2010-06-18 |
2011-12-22 |
Xiberscience Gmbh |
Peptides as active agents to stabilize biological barriers
|
SG187736A1
(en)
|
2010-08-17 |
2013-03-28 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
TWI480288B
(en)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
Formulations for bovine granulocyte colony stimulating factor and variants thereof
|
CN103261412B
(en)
|
2010-09-28 |
2016-03-23 |
积水化学工业株式会社 |
Anti-human CCR7 antibody, hybridoma, nucleic acid, carrier, cell, medical composition and antibody immobilization carrying body
|
MX2013004679A
(en)
|
2010-10-25 |
2014-02-20 |
Univ Minnesota |
Therapeutic composition for treatment of glioblastoma.
|
TWI636994B
(en)
|
2010-10-27 |
2018-10-01 |
安美基公司 |
Dkk1 antibodies and methods of use
|
SG190088A1
(en)
|
2010-11-01 |
2013-06-28 |
Peptimed Inc |
Compositions of a peptide targeting system for treating cancer
|
TWI452135B
(en)
|
2010-11-17 |
2014-09-11 |
中外製藥股份有限公司 |
A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
CN103298490B
(en)
|
2010-11-24 |
2017-04-26 |
莱克康制药公司 |
Antibodies to notum pectinacetylesterase
|
CA2819501C
(en)
|
2010-11-30 |
2020-03-31 |
The Johns Hopkins University |
Hybrid cyclic libraries and screens thereof
|
SI2647707T1
(en)
|
2010-11-30 |
2018-12-31 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
ES2626418T3
(en)
|
2010-12-23 |
2017-07-25 |
Hanall Biopharma Co., Ltd. |
Modified polypeptide of human tumor necrosis factor-1 receptor or fragment thereof and preparation process thereof
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
WO2012102679A1
(en)
|
2011-01-24 |
2012-08-02 |
National University Of Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
RS56461B1
(en)
|
2011-01-27 |
2018-01-31 |
Neuren Pharmaceuticals Ltd |
Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
|
AU2012223358A1
(en)
|
2011-03-01 |
2013-09-05 |
Amgen Inc. |
Sclerostin and DKK-1 bispecific binding agents
|
CN103533928A
(en)
|
2011-03-10 |
2014-01-22 |
霍夫曼-拉罗奇有限公司 |
Treatment of disorders with altered vascular barrier function
|
KR20140027211A
(en)
|
2011-04-04 |
2014-03-06 |
유니버시티 오브 아이오와 리써치 파운데이션 |
Methods of improving vaccine immunogenicity
|
AU2012239997A1
(en)
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
EP2694092B1
(en)
|
2011-04-08 |
2017-01-04 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
EP3449933A1
(en)
|
2011-04-29 |
2019-03-06 |
University of Washington |
Therapeutic nuclease compositions and methods
|
US20140178398A1
(en)
|
2011-05-03 |
2014-06-26 |
Genentech, Inc |
Vascular disruption agents and uses thereof
|
JOP20200043A1
(en)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
Methods of treating or preventing cholesterol related disorders
|
AU2012254160A1
(en)
|
2011-05-10 |
2013-11-21 |
Amgen Inc. |
Method of identifying compounds that specifically modulate the interaction of FGFR1 and beta-Klotho
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
CN103917093B
(en)
|
2011-06-14 |
2017-08-11 |
比卡姆药品公司 |
Opsin binding partner, composition and application method
|
JP2014520123A
(en)
|
2011-06-17 |
2014-08-21 |
アムジエン・インコーポレーテツド |
Methods of treating or ameliorating metabolic disorders using CLEC-2
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
US9605083B2
(en)
|
2011-08-16 |
2017-03-28 |
Emory University |
JAML specific binding agents, antibodies, and uses related thereto
|
CA2843369A1
(en)
|
2011-08-16 |
2013-02-21 |
Evotec (Munchen) Gmbh |
Markers for susceptibility to an inhibitor of an src-family kinase
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
WO2013033452A2
(en)
|
2011-08-31 |
2013-03-07 |
Amgen Inc. |
Method of treating or ameliorating type 1 diabetes using fgf21
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
AP2014007588A0
(en)
|
2011-09-22 |
2014-04-30 |
Amgen Inc |
CD27L antigen binding proteins
|
JO3476B1
(en)
|
2011-09-26 |
2020-07-05 |
Novartis Ag |
Fusion proteins for treating metabolic disorders
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
CA2850322C
(en)
|
2011-09-30 |
2023-10-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
WO2013056255A1
(en)
|
2011-10-14 |
2013-04-18 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for inhibiting tumor cell proliferation
|
EP2768307B1
(en)
|
2011-10-19 |
2020-03-18 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
KR20140091064A
(en)
|
2011-11-16 |
2014-07-18 |
암젠 인크 |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
GR1007832B
(en)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Activin neutralisers and uses thereof for treatment of diseases associated with aberrant "host defence response" activation
|
CA2862807A1
(en)
|
2011-11-30 |
2013-06-06 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
CA2862746A1
(en)
|
2011-12-01 |
2013-06-06 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
WO2013086443A1
(en)
|
2011-12-08 |
2013-06-13 |
Amgen Inc. |
Agonistic human lcat antigen binding proteins and their use in therapy
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
CN104144946A
(en)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
Methods for treating acne
|
EA201491231A8
(en)
|
2011-12-19 |
2015-01-30 |
Амген Инк. |
OPTIONS FOR ACTIVIN RECEPTOR POLYPEPTIDES AND THEIR APPLICATION
|
WO2013106485A2
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
JP2015509091A
(en)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
Humanized antibody
|
WO2013106572A1
(en)
|
2012-01-11 |
2013-07-18 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
WO2013113008A1
(en)
|
2012-01-26 |
2013-08-01 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) polypeptides
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
KR101893632B1
(en)
|
2012-02-17 |
2018-08-30 |
키네타 포 엘엘씨 |
Antiviral drugs for treatment of arenavirus infection
|
EP2831277A4
(en)
|
2012-03-29 |
2016-06-29 |
Univ Colorado |
Click nucleic acids
|
CA2871417C
(en)
|
2012-04-23 |
2021-08-31 |
Genefrontier Corporation |
Anti-human cd69 antibody, and use thereof for medical purposes
|
EA039663B1
(en)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
|
JO3623B1
(en)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
St2 antigen binding proteins
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
MX2014014234A
(en)
|
2012-05-22 |
2015-05-07 |
Genentech Inc |
N-substituted benzamides and their use in the treatment of pain.
|
JP6267193B2
(en)
|
2012-05-22 |
2018-01-24 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Substituted dipyridylamines and their use
|
WO2014006063A2
(en)
|
2012-07-02 |
2014-01-09 |
Medizinische Universität Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
CA2878478A1
(en)
|
2012-07-06 |
2014-01-09 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
JP2015526471A
(en)
|
2012-08-21 |
2015-09-10 |
ジェネシス リサーチ インスティチュート |
Compositions and methods for treating or preventing anthracycline-induced cardiotoxicity
|
CN104684899B
(en)
|
2012-09-27 |
2017-07-04 |
霍夫曼-拉罗奇有限公司 |
Substituted sulfonamide compounds
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
EA034163B1
(en)
|
2012-10-17 |
2020-01-13 |
Васкьюлар Байодженикс Лтд. |
Nucleic acid construct comprising an endothelial cell-specific promoter and antitumor use thereof
|
EP3473718A1
(en)
|
2012-11-09 |
2019-04-24 |
GeneFrontier Corporation |
Anti-adam28 antibody for treating cancer
|
UY35148A
(en)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
HETERODIMERIC IMMUNOGLOBULINS
|
KR102291355B1
(en)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
TW201425336A
(en)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
BCMA antigen binding proteins
|
TWI498325B
(en)
|
2013-01-18 |
2015-09-01 |
Hoffmann La Roche |
3-substituted pyrazoles and uses thereof
|
ES2728936T3
(en)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Antibodies directed against CDH19 for melanoma
|
JO3519B1
(en)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
Antibody constructs for CDH19 and CD3
|
EA201591423A1
(en)
|
2013-02-01 |
2016-01-29 |
Санта Мария Биотерапевтикс, Инк. |
INTRODUCTION OF ANTIBODIES TO ACTIVINE-A TO PATIENTS
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(en)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
US9550775B2
(en)
|
2013-03-14 |
2017-01-24 |
Genentech, Inc. |
Substituted triazolopyridines and methods of use thereof
|
EP2970451A1
(en)
|
2013-03-14 |
2016-01-20 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
US9474792B2
(en)
|
2013-03-15 |
2016-10-25 |
Amgen Inc. |
Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
|
AU2014236867A1
(en)
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Methods and compositions relating to anti-CCR7 antigen binding proteins
|
EP2970470B1
(en)
|
2013-03-15 |
2019-12-04 |
Amgen Inc. |
Human pac1 antibodies
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
UY35484A
(en)
|
2013-03-15 |
2014-10-31 |
Amgen Res Munich Gmbh |
Single chain binding molecule comprising N-end ABP
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
TW201800403A
(en)
|
2013-05-01 |
2018-01-01 |
赫孚孟拉羅股份公司 |
Biheteroaryl compounds and uses thereof
|
MX2015014861A
(en)
|
2013-05-01 |
2016-03-09 |
Hoffmann La Roche |
C-linked heterocycloalkyl substituted pyrimidines and their uses.
|
EP3461909A1
(en)
|
2013-05-21 |
2019-04-03 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
US10098834B2
(en)
|
2013-05-22 |
2018-10-16 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for treating heart failure
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
US9663571B2
(en)
|
2013-05-30 |
2017-05-30 |
Kiniksa Pharmaceuticals, Ltd. |
Oncostatin M receptor antigen binding proteins
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
PT3019533T
(en)
|
2013-07-11 |
2020-04-17 |
Scripps Research Inst |
Coiled coil immunoglobulin fusion proteins and compositions thereof
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
PL3027642T3
(en)
|
2013-07-31 |
2021-01-11 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) constructs
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
TW201605896A
(en)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
GITR antigen binding proteins
|
CA2923145A1
(en)
|
2013-09-05 |
2015-03-12 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
US11465978B2
(en)
|
2013-09-11 |
2022-10-11 |
The Administrators Of The Tulane Educational Fund |
Anthranilic amides and the use thereof
|
EP3043824B1
(en)
|
2013-09-13 |
2022-07-06 |
The Scripps Research Institute |
Modified therapeutic agents and compositions thereof
|
AR097648A1
(en)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA
|
PL2808338T3
(en)
|
2013-09-16 |
2016-09-30 |
|
Mutant calreticulin for the diagnosis of myeloid malignancies
|
EP3047857A4
(en)
|
2013-09-20 |
2017-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
WO2015048331A1
(en)
|
2013-09-25 |
2015-04-02 |
Cornell University |
Compounds for inducing anti-tumor immunity and methods thereof
|
US20150104392A1
(en)
|
2013-10-04 |
2015-04-16 |
Aptose Biosciences Inc. |
Compositions, biomarkers and their use in the treatment of cancer
|
JP2016532673A
(en)
|
2013-10-11 |
2016-10-20 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
|
ES2845924T3
(en)
|
2013-10-15 |
2021-07-28 |
Scripps Research Inst |
T-cell switches with peptide chimeric antigen receptors and their uses
|
CN105814083A
(en)
|
2013-10-15 |
2016-07-27 |
加州生物医学研究所 |
Chimeric antigen receptor T cell switches and uses thereof
|
CN105849128B
(en)
|
2013-10-15 |
2019-10-11 |
基因先端领域株式会社 |
The human antibody for aggrecan enzyme type ADAMTS type for aggrecan enzyme treating correlative diseases
|
US20160235810A1
(en)
|
2013-10-18 |
2016-08-18 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
EP3063275B1
(en)
|
2013-10-31 |
2019-09-25 |
Resolve Therapeutics, LLC |
Therapeutic nuclease-albumin fusions and methods
|
WO2015095406A1
(en)
|
2013-12-18 |
2015-06-25 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
MX2016008110A
(en)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Pyrazole derivatives and uses thereof as inhibitors of dlk.
|
CN103965357B
(en)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
A kind of anti-human RANKL antibody
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
EP3104873B1
(en)
|
2014-02-13 |
2019-09-04 |
Technische Universität München |
Fgf-8 for use in treating diseases or disorders of energy homeostasis
|
RU2019119862A
(en)
|
2014-02-20 |
2019-07-15 |
Аллерган, Инк. |
ANTIBODY TO C5 COMPLETE COMPONENT
|
SG10202104175YA
(en)
|
2014-02-27 |
2021-06-29 |
Allergan Inc |
COMPLEMENT FACTOR Bb ANTIBODIES
|
CN106458856A
(en)
|
2014-03-07 |
2017-02-22 |
约翰霍普金斯大学 |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
US10507227B2
(en)
|
2014-04-15 |
2019-12-17 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
US20170073690A1
(en)
|
2014-05-15 |
2017-03-16 |
CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH |
Antagonists of slc38a9 and their use in therapy
|
WO2015179415A1
(en)
|
2014-05-19 |
2015-11-26 |
Novartis Ag |
Methods of treating anorexia
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
WO2015184260A2
(en)
|
2014-05-30 |
2015-12-03 |
The Johns Hopkins University |
Methods for treating mendelian disorders of the epigenetic machinery
|
KR102015451B1
(en)
|
2014-06-03 |
2019-08-28 |
엑스바이오테크, 인크. |
Compositions and methods for treating and preventing staphylococcus aureus infections
|
CN106604743A
(en)
|
2014-06-09 |
2017-04-26 |
奥特吉尼克斯制药公司 |
The effective and efficient control of serum phosphate for optimal bone formation
|
AU2015274293A1
(en)
|
2014-06-13 |
2017-02-02 |
Amgen Inc. |
Formulated receptor polypeptides and related methods
|
TW201625299A
(en)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
|
WO2016007534A1
(en)
|
2014-07-07 |
2016-01-14 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
WO2016007919A2
(en)
|
2014-07-11 |
2016-01-14 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
AU2015294834B2
(en)
|
2014-07-31 |
2021-04-29 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
UY36245A
(en)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
CA2957717C
(en)
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
US10465188B2
(en)
|
2014-08-22 |
2019-11-05 |
Auckland Uniservices Limited |
Channel modulators
|
AU2015307186A1
(en)
|
2014-08-27 |
2017-04-13 |
Peptimed, Inc. |
Anti-tumor compositions and methods
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
ES2882080T3
(en)
|
2014-10-21 |
2021-12-01 |
Sciclone Pharmaceuticals Int Ltd |
Cancer treatment with immune stimulators
|
TW202124419A
(en)
|
2014-10-24 |
2021-07-01 |
美商必治妥美雅史谷比公司 |
Modified fgf-21 polypeptides and uses thereof
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
EP3250609A4
(en)
|
2015-01-26 |
2018-07-11 |
The University of Chicago |
Il13ra alpha 2 binding agents and use thereof in cancer treatment
|
JP6912386B2
(en)
|
2015-01-26 |
2021-08-04 |
ザ ユニバーシティー オブ シカゴ |
CAR T cells that recognize cancer-specific IL13Rα2
|
US10906948B2
(en)
|
2015-02-23 |
2021-02-02 |
Seagull Therapeutics Sas |
Non-natural Semaphorins 3 and their medical use
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
RU2730590C2
(en)
|
2015-02-27 |
2020-08-24 |
Чугаи Сейяку Кабусики Кайся |
Composition for treating diseases associated with il-6
|
CN107406462B
(en)
|
2015-03-09 |
2020-11-10 |
豪夫迈·罗氏有限公司 |
Tricyclic DLK inhibitors and uses thereof
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
IL283764B2
(en)
|
2015-04-10 |
2024-01-01 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
WO2016168773A2
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
TWI772258B
(en)
|
2015-04-17 |
2022-08-01 |
德商安美基研究(慕尼黑)公司 |
Bispecific antibody constructs for cdh3 and cd3
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
WO2016186977A1
(en)
|
2015-05-15 |
2016-11-24 |
The Johns Hopkins University |
Novel fluoride prenatal dietary supplement
|
CR20170591A
(en)
|
2015-05-22 |
2018-05-07 |
Genentech Inc |
BENZAMIDS REPLACED AND METHODS TO USE THEM
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
US20190000928A1
(en)
|
2015-06-17 |
2019-01-03 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
WO2017007955A1
(en)
|
2015-07-07 |
2017-01-12 |
The Research Foundation For The State University Of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
TWI796283B
(en)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for msln and cd3
|
CA2994162A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Glutamine antagonists for the treatment of cognitive deficits
|
WO2017023787A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Methods and compositions for treating metabolic reprogramming disorders
|
TWI793062B
(en)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for dll3 and cd3
|
TWI829617B
(en)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for flt3 and cd3
|
TWI717375B
(en)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for cd70 and cd3
|
US10842763B2
(en)
|
2015-07-31 |
2020-11-24 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
|
FI3328827T3
(en)
|
2015-07-31 |
2023-09-26 |
Univ Johns Hopkins |
Prodrugs of glutamine analogs
|
TWI744242B
(en)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for egfrviii and cd3
|
JO3620B1
(en)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers
|
MA42683A
(en)
|
2015-08-27 |
2018-07-04 |
Genentech Inc |
THERAPEUTIC COMPOUNDS AND THEIR METHODS OF USE
|
EP3344278A4
(en)
|
2015-09-04 |
2019-01-23 |
The California Institute for Biomedical Research |
Insulin immunoglobulin fusion proteins
|
US20180280474A1
(en)
|
2015-10-01 |
2018-10-04 |
Amgen Inc. |
Treatment of bile acid disorders
|
CN108350077A
(en)
|
2015-11-03 |
2018-07-31 |
糖模拟物有限公司 |
Generate monoclonal antibody, the method and composition of candidate stem cell and the method using the antibody and candidate stem cell
|
CA3004680A1
(en)
|
2015-11-13 |
2017-05-18 |
Mavalon Therapeutics Limited |
Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
JP6931329B2
(en)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
|
JP2018535234A
(en)
|
2015-11-25 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
Substituted benzamides useful as sodium channel blockers
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
MX2018006953A
(en)
|
2015-12-09 |
2019-05-16 |
Univ Wien Med |
Monomaleimide-functionalized platinum compounds for cancer therapy.
|
DK3387019T3
(en)
|
2015-12-09 |
2022-01-10 |
Scripps Research Inst |
RELAXIN-IMMUNOGLOBULIN INFUSION PROTEINS AND METHODS OF USE
|
US20200270363A1
(en)
|
2015-12-25 |
2020-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
WO2017121855A1
(en)
|
2016-01-15 |
2017-07-20 |
Universität Hamburg |
Flavonoide-type compounds bearing an o-rhamnosyl residue
|
JOP20170017B1
(en)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
Pharmaceutical composition comprising bispecific antibody constructs
|
LT3411402T
(en)
|
2016-02-03 |
2022-01-25 |
Amgen Research (Munich) Gmbh |
Bcma and cd3 bispecific t cell engaging antibody constructs
|
EA201891753A1
(en)
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
BISPECIFIC CONSTRUCTIONS OF ANTIBODIES TO PSMA AND CD3, INVOLVING T-CELLS
|
EA039859B1
(en)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Bispecific antibody constructs binding egfrviii and cd3
|
US10098909B2
(en)
|
2016-02-05 |
2018-10-16 |
University Of South Florida |
Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
|
EP3414573B1
(en)
|
2016-02-10 |
2023-11-08 |
Rutgers, the State University of New Jersey |
Novel anti-lam antibodies
|
KR20180134860A
(en)
|
2016-02-15 |
2018-12-19 |
체엠엠 - 포르슝스첸트룸 퓨어 몰레쿨라레 메디친 게엠베하 |
TAF1 inhibitor for the treatment of cancer
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
SG10202007025PA
(en)
|
2016-03-14 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Cell injury inducing therapeutic drug for use in cancer therapy
|
EP3854782A1
(en)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
GB2555264A
(en)
|
2016-04-15 |
2018-04-25 |
Univ Oxford Innovation Ltd |
Adenosine receptor modulators for the treatment of circadian rhythm disorders
|
CN109071623B
(en)
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
Interleukin-2 muteins for expansion of T regulatory cells
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
CA3029627A1
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
WO2018013924A1
(en)
|
2016-07-15 |
2018-01-18 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
JP7043483B2
(en)
|
2016-07-20 |
2022-03-29 |
エフ.ホフマン-ラ ロシュ アーゲー |
Bicyclic proline compound
|
EP3487849A1
(en)
|
2016-07-20 |
2019-05-29 |
H. Hoffnabb-La Roche Ag |
Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
WO2018024654A1
(en)
|
2016-08-02 |
2018-02-08 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
CA3032348A1
(en)
|
2016-08-08 |
2018-02-15 |
Amgen Inc. |
Method of improving connective tissue attachment using anti-sclerostin antibodies
|
WO2018029288A1
(en)
|
2016-08-12 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Sulfonyl pyridyl trp inhibitors
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
CN109790125B
(en)
|
2016-09-16 |
2022-07-05 |
研究三角协会 |
Tetrahydroisoquinoline kappa opioid antagonists
|
WO2018073193A1
(en)
|
2016-10-17 |
2018-04-26 |
F. Hoffmann-La Roche Ag |
Bicyclic pyridone lactams and methods of use thereof
|
JP7149935B2
(en)
|
2016-10-19 |
2022-10-07 |
ザ スクリプス リサーチ インスティテュート |
Chimeric Antigen Receptor Effector Cell Switches with Humanized Targeting Moieties and/or Optimized Chimeric Antigen Receptor Interacting Domains and Uses Thereof
|
EP3538100A2
(en)
|
2016-11-14 |
2019-09-18 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
|
CN110225911B
(en)
|
2016-11-28 |
2022-04-05 |
豪夫迈·罗氏有限公司 |
Oxadiazolone transient receptor potential channel inhibitors
|
EP3548488A1
(en)
|
2016-11-30 |
2019-10-09 |
Oncotyrol Center for Personalized Cancer Medicine GmbH |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
|
WO2018100070A1
(en)
|
2016-12-02 |
2018-06-07 |
F. Hoffmann-La Roche Ag |
Bicyclic amide compounds and methods of use thereof
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
WO2018128454A1
(en)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
ANTI-α-SYN ANTIBODY AND USE THEREOF
|
CA3049656A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
WO2018130554A1
(en)
|
2017-01-11 |
2018-07-19 |
Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung |
Mesenchymal stem cell-derived extracellular vesicles and their medical use
|
JOP20190189A1
(en)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
Low ph pharmaceutical composition comprising t cell engaging antibody constructs
|
AU2018219283B2
(en)
|
2017-02-08 |
2022-05-19 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
WO2018160791A1
(en)
|
2017-03-03 |
2018-09-07 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
CN114874209A
(en)
|
2017-03-07 |
2022-08-09 |
豪夫迈·罗氏有限公司 |
Oxadiazole transient receptor potential channel inhibitors
|
CN110546148A
(en)
|
2017-03-24 |
2019-12-06 |
基因泰克公司 |
4-piperidine-N- (pyrimidin-4-yl) chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
|
UY37726A
(en)
|
2017-05-05 |
2018-11-30 |
Amgen Inc |
PHARMACEUTICAL COMPOSITION THAT INCLUDES BISPECTIFIC ANTIBODY CONSTRUCTIONS FOR IMPROVED STORAGE AND ADMINISTRATION
|
AU2018265584B2
(en)
|
2017-05-12 |
2023-09-28 |
Ludwig-Maximilians-Universität München |
Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
|
CA3063288A1
(en)
|
2017-05-12 |
2018-11-15 |
Mavalon Therapeutics Limited |
Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
|
JOP20190259A1
(en)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
Anti-jagged1 antigen binding proteins
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
MX2019013919A
(en)
|
2017-06-20 |
2020-01-21 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists.
|
AU2018301393A1
(en)
|
2017-07-11 |
2020-02-06 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
SG11202000333UA
(en)
|
2017-07-14 |
2020-02-27 |
Hoffmann La Roche |
Bicyclic ketone compounds and methods of use thereof
|
WO2019018691A1
(en)
|
2017-07-19 |
2019-01-24 |
Auckland Uniservices Limited |
Cytokine modulation
|
EP3665202A1
(en)
|
2017-08-09 |
2020-06-17 |
Massachusetts Institute Of Technology |
Albumin binding peptide conjugates and methods thereof
|
BR112020003670A2
(en)
|
2017-08-22 |
2020-09-01 |
Sanabio, Llc |
soluble interferon receptors and their uses
|
WO2019060425A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
SG11202003114UA
(en)
|
2017-10-04 |
2020-05-28 |
Amgen Inc |
Transthyretin immunoglobulin fusions
|
MA50356A
(en)
|
2017-10-11 |
2021-04-21 |
Hoffmann La Roche |
BICYCLIC COMPOUNDS INTENDED FOR USE AS KINASE RIP1 INHIBITORS
|
KR20200074160A
(en)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
Pharmaceutical composition for inhibiting post-surgical adhesion containing anti-IL-6 receptor antibody
|
US11066438B2
(en)
|
2017-10-30 |
2021-07-20 |
Enterin, Inc. |
Squalamine solid forms and methods of making the same
|
EP3704097B1
(en)
|
2017-10-31 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Bicyclic sulfones and sulfoxides and methods of use thereof
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
EP3720850A1
(en)
|
2017-12-05 |
2020-10-14 |
ETH Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
BR112020011627A2
(en)
|
2017-12-11 |
2020-11-17 |
Amgen Inc. |
continuous manufacturing process for bispecific antibody products
|
EP3727447A1
(en)
|
2017-12-19 |
2020-10-28 |
Massachusetts Institute of Technology |
Antigen-adjuvant coupling reagents and methods of use
|
EP3732195A4
(en)
|
2017-12-28 |
2022-02-09 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
TW201940518A
(en)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
Bispecific antibody construct directed to MUC17 and CD3
|
EP3747469A4
(en)
|
2018-01-31 |
2022-03-23 |
Motokazu Kato |
Therapeutic agent for asthma containing il-6 inhibitor
|
MX2020008193A
(en)
|
2018-02-09 |
2020-11-24 |
Nestle Skin Health Sa |
Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation.
|
TW202000201A
(en)
|
2018-02-20 |
2020-01-01 |
瑞士商赫孚孟拉羅股份公司 |
Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide Transient Receptor Potential channel antagonist compounds and crystalline forms thereof
|
CN112041313A
(en)
|
2018-02-26 |
2020-12-04 |
基因泰克公司 |
Pyridine-sulfonamide compounds and their use against pain and related conditions
|
NZ767596A
(en)
|
2018-03-14 |
2022-01-28 |
Surface Oncology Inc |
Antibodies that bind cd39 and uses thereof
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
WO2019183499A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
EP3774801A1
(en)
|
2018-03-30 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Fused ring hydro-pyrido compounds as sodium channel inhibitors
|
SG11202008206TA
(en)
|
2018-03-30 |
2020-09-29 |
Amgen Inc |
C-terminal antibody variants
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
WO2019193159A1
(en)
|
2018-04-06 |
2019-10-10 |
Universität Wien |
Bumetanide derivatives for the therapy of hyperhidrosis
|
PE20201350A1
(en)
|
2018-04-09 |
2020-11-30 |
Amgen Inc |
FUSION PROTEINS OF THE GROWTH DIFFERENTIATION FACTOR 15
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US10907161B2
(en)
|
2018-04-19 |
2021-02-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
JP7398391B2
(en)
|
2018-04-20 |
2023-12-14 |
エフ. ホフマン-ラ ロシュ アーゲー |
N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxamide derivative and Related compounds as RIP1 kinase inhibitors, for example to treat irritable bowel syndrome (IBS)
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
TW202003580A
(en)
|
2018-05-21 |
2020-01-16 |
美商坎伯斯治療有限責任公司 |
Compositions and methods for enhancing the killing of target cells by NK cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
TW202003490A
(en)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
Therapeutic compounds and methods of use thereof
|
WO2019225787A1
(en)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
Anti-b7-h3 antibody and use thereof
|
WO2020011938A1
(en)
|
2018-07-11 |
2020-01-16 |
Medizinische Universität Wien |
Glucocorticoids for the topical treatment of autoimmune gastritis
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
BR112021003843A2
(en)
|
2018-08-28 |
2021-05-25 |
Ambrx, Inc. |
anti-cd3 antibody folate biconjugates and their uses
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
CN116948006A
(en)
|
2018-09-11 |
2023-10-27 |
北京泰德制药股份有限公司 |
Interleukin-2polypeptide conjugate and use thereof
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
SG11202100935TA
(en)
|
2018-09-28 |
2021-02-25 |
Massachusetts Inst Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
MX2021003976A
(en)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Downstream processing of bispecific antibody constructs.
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
US20230067929A1
(en)
|
2018-12-17 |
2023-03-02 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
BR112021013096A2
(en)
|
2019-01-04 |
2022-04-19 |
Resolve Therapeutics, Llc |
TREATMENT OF SJÖGREN'S DISEASE WITH NUCLEASE FUSION PROTEINS
|
CN113302193A
(en)
|
2019-01-11 |
2021-08-24 |
豪夫迈·罗氏有限公司 |
Bicyclic pyrrolotriazolone compounds and methods of use thereof
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
US11235032B2
(en)
|
2019-01-23 |
2022-02-01 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
US11236157B2
(en)
|
2019-01-28 |
2022-02-01 |
Galderma Holding SA |
Treatment of skin lesions and pruritus in prurigo nodularis patients
|
WO2020168017A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
US20200345853A1
(en)
|
2019-03-20 |
2020-11-05 |
Massachusetts Institute Of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
KR20210144795A
(en)
|
2019-03-29 |
2021-11-30 |
추가이 세이야쿠 가부시키가이샤 |
Inhibitors of BBB Function Decrease Containing Anti-IL-6 Receptor Antibodies
|
US20220204608A1
(en)
|
2019-04-17 |
2022-06-30 |
Hiroshima University |
Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
|
CN113924119A
(en)
|
2019-05-31 |
2022-01-11 |
国立大学法人大阪大学 |
Novel therapeutic agent for digestive organ cancer and method for screening same
|
TW202112808A
(en)
|
2019-06-05 |
2021-04-01 |
日商中外製藥股份有限公司 |
Antibody cleavage site-binding molecule
|
EP3981429A4
(en)
|
2019-06-10 |
2023-07-26 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
|
CA3137494A1
(en)
|
2019-06-13 |
2020-12-17 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
WO2020263399A1
(en)
|
2019-06-26 |
2020-12-30 |
Massachusetts Institute Of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
SG11202112762TA
(en)
|
2019-07-08 |
2021-12-30 |
Amgen Inc |
Multispecific transthyretin immunoglobulin fusions
|
KR20220033493A
(en)
|
2019-07-10 |
2022-03-16 |
추가이 세이야쿠 가부시키가이샤 |
Claudine 6 Binding Molecules and Their Uses
|
CA3148591A1
(en)
|
2019-07-26 |
2021-02-04 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
AU2020328507A1
(en)
|
2019-08-12 |
2022-03-17 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
JOP20220036A1
(en)
|
2019-08-13 |
2023-01-30 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
AU2020351122A1
(en)
|
2019-09-16 |
2022-02-17 |
Surface Oncology, Inc. |
Anti-CD39 antibody compositions and methods
|
CA3151078A1
(en)
|
2019-09-25 |
2021-04-01 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
CN114728934A
(en)
|
2019-10-02 |
2022-07-08 |
托雷莫治疗股份公司 |
Heterocyclic derivatives, pharmaceutical compositions and their use for treating or ameliorating cancer
|
TWI745114B
(en)
|
2019-10-11 |
2021-11-01 |
日商中外製藥股份有限公司 |
Pharmaceutical composition for the prevention and/or treatment of acquired hemophilia A, and products containing the pharmaceutical composition
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
AU2020366135A1
(en)
|
2019-10-16 |
2022-06-02 |
Proxygen Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
CA3155202A1
(en)
|
2019-10-23 |
2021-04-29 |
Arthur M. Krieg |
Synthetic rig-i-like receptor agonists
|
EP4048405A2
(en)
|
2019-10-24 |
2022-08-31 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
MX2022005775A
(en)
|
2019-11-13 |
2022-06-09 |
Genentech Inc |
Therapeutic compounds and methods of use.
|
WO2021097344A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
CN114728927A
(en)
|
2019-11-19 |
2022-07-08 |
莫达戈有限公司 |
Novel compounds for the diagnosis, treatment and prevention of diseases associated with aggregation of alpha-synuclein
|
CN114867749A
(en)
|
2019-12-17 |
2022-08-05 |
安进公司 |
Dual interleukin-2/TNF receptor agonists for use in therapy
|
EP4087607A1
(en)
|
2020-01-06 |
2022-11-16 |
Vaccinex, Inc. |
Anti-ccr8 antibodies and uses thereof
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
EP4117732A1
(en)
|
2020-03-11 |
2023-01-18 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
MX2022011632A
(en)
|
2020-03-19 |
2022-10-13 |
Amgen Inc |
Antibodies against mucin 17 and uses thereof.
|
JP2023106635A
(en)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021248081A1
(en)
|
2020-06-05 |
2021-12-09 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Acvr1 (alk2) receptor inhibition to treat neurological diseases
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
JP7250219B2
(en)
|
2020-06-19 |
2023-03-31 |
中外製薬株式会社 |
ANTI-T-CELL ANTIGEN-BINDING MOLECULES FOR USE IN COMBINATION WITH ANGIOGENIC INHIBITORS
|
WO2021260110A1
(en)
|
2020-06-25 |
2021-12-30 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
EP4171614A1
(en)
|
2020-06-29 |
2023-05-03 |
Resolve Therapeutics, LLC |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
AU2021317974A1
(en)
|
2020-07-31 |
2023-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
CA3190606A1
(en)
|
2020-08-20 |
2022-02-24 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
AU2021353532A1
(en)
|
2020-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Process for the preparation of biheteroaryl compounds and crystal forms thereof
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
EP4240768A2
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
CN117321076A
(en)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
Single domain antibodies neutralizing SARS-CoV-2
|
EP4306127A1
(en)
|
2021-03-12 |
2024-01-17 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for treatment or prevention of myasthenia gravis
|
WO2022212899A1
(en)
|
2021-04-03 |
2022-10-06 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
CA3212085A1
(en)
|
2021-04-07 |
2022-10-13 |
Charles-Henry Fabritius |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
US20220389089A1
(en)
|
2021-05-07 |
2022-12-08 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
TW202310868A
(en)
|
2021-05-14 |
2023-03-16 |
美商克拉里斯生物醫療股份有限公司 |
Compositions of growth factor for the treatment of eye disease
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
CA3229982A1
(en)
|
2021-08-30 |
2023-03-09 |
Galderma Holding SA |
Treatments for atopic dermatitis
|
CA3230815A1
(en)
|
2021-09-03 |
2023-03-09 |
University Of Bern |
Compositions and methods for treating long ot syndrome
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
TW202334221A
(en)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
Bispecific cd16a binders
|
TW202332429A
(en)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
WO2023203378A1
(en)
|
2022-04-19 |
2023-10-26 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
US20240026001A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2023230116A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2024047497A1
(en)
|
2022-09-02 |
2024-03-07 |
Galderma Holding SA |
Treatments for prurigo nodularis
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|